CLRB and CLRBZ Related Headlines
Go Back- Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
- Cellectar reports 12-month data for cancer drug in rare blood disorder
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
- Cellectar Biosciences raises up to $140 million in oversubscribed financing
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
- Cellectar enrolls first patient in breast cancer drug trial
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
- Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
CLRB and CLRBZ Related Press Releases
Go Back- Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
- Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
